CILIATECH - Glaucoma Innovators

Ciliatech is a French medtech company focused on ophthalmology, particularly in developing advanced treatments for glaucoma, a leading cause of irreversible blindness affecting millions worldwide. Founded in 2017 by Dr. Philippe Sourdille and Olivier Benoit, the company is based near Annecy, France, and has raised around €12 million to date. The company's flagship product, the Intercil® Uveal Spacer, is a novel implant designed to lower intraocular pressure by being placed in the supraciliary space of the eye. This innovative approach helps avoid common complications associated with other minimally invasive glaucoma surgery devices. Intercil® effectively treats both open-angle and narrow-angle glaucoma, expanding treatment options in the market. Ciliatech is also conducting clinical trials for a second-generation version of the device. Ciliatech provides comprehensive support and training for surgeons through its Concierge Access program, which includes a digital learning platform, instructional courses, and hands-on surgical simulation training. The company aims to offer safer and more effective alternatives to existing glaucoma therapies, addressing a significant need for durable management with minimal adverse effects.

• Employees 8
• Founded 2017
• Total Funding $4000000